Psychiatr. pro Praxi, 2009; 10(3): 117-121

Concepts of evaluation of the long-term treatment of schizophrenia

doc. MUDr. Ján Pečeňák, CSc, MUDr. Mgr. Helena Aziri
Psychiatrická klinika FN a LF UK Bratislava

Long-term treatment with antipsychotics is a standard recommendation in the treatment of schizophrenia. The effectiveness of treatment

depends on many factors like prevailing symptomatology and type of schizophrenia, patient’s adherence to treatment and natural course

of schizophrenia. These factors interfere with an evaluation of treatment effect mainly if the principles of Evidence Based Medicine are

applied. The main goal of the article is to mention some aspects of long-term antipsychotic treatment that could help in understanding

of results in published clinical studies and transforming these data to clinical practice.

Keywords: schizophrenia, long-term treatment, evidence based medicine.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pečeňák J, Aziri H. Concepts of evaluation of the long-term treatment of schizophrenia. Psychiatr. praxi. 2009;10(3):117-121.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Expert Consensus Treatment Guidelines for Schizophrenia: a Guide for patiens and families. Treatment of schizophrenia 1999. The expert consensus guideline series. J Clin Psychiatry 1999; 60 Suppl 11: 3-80.
    2. Smolík P. Duševní a behaviorální poruchy. Maxdorf: Praha 1996: 504 s.
    3. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 29, 371(9618): 1085-1097. Go to original source... Go to PubMed...
    4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209-1223. Go to original source... Go to PubMed...
    5. Ohmori T, Ito K, Abekawa T, Koyama T. Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up. Eur Arch Psychiatry Clin Neurosci 1999; 249(2): 73-78. Go to original source... Go to PubMed...
    6. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373(9657): 31-41. Go to original source... Go to PubMed...
    7. Seifertová D, Libiger J, Švestka J, Mohr P, Motlová L. Schizofrenie. In: Sefertová D, Praško J, Horáček J, Höschl C. Postupy vléčbě psychických poruch. Algoritmy České neuropsychoframkologické společnosti. 2. revidované vydání. Academia medica pragensis 2008: 82-101 s.
    8. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res. 2005; 79(2-3): 231-238. Go to original source... Go to PubMed...
    9. Pečeňák J. Štúdia IC-SOHO - vybrané výsledky v Českej a Slovenskej republike. Psychiatrie pro praxi 2008; (Suppl. 1): 10-14.
    10. Haro JM, Ochoa S, Gervin M, Mavreas V, Jones P. Assessment of remission in schizophrenia with the CGI and CGI-SCH scales. Acta Psychiatr Scand 2007; 115(2): 163-164. Go to original source... Go to PubMed...
    11. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR.: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449. Go to original source... Go to PubMed...
    12. Tůma I, Pečeňák J, Mohr P, Češková E, Anders M. Risperdal Consta - dlouhodobě pusobící injekce v léčbě schizofrenie a schizoafektivni poruchy: předběžné 12měsíční výsledky projektu e-STAR v České a Slovenske republice. Čes. a slov. Psychiat 2008; 104(2): 59-67.
    13. Jäger M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüther E, Buchkremer G, Gastpar M, Riedel M, Bottlender R, Strauss A, Möller HJ. Standardized remission criteria in schizophrenia: descriptive validity and comparability with previously used outcome measures. Pharmacopsychiatry 2008; 41(5): 190-195. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.